1. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?;Grobner;Nephrol Dial Transplant,2006
2. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging;Marckmann;J Am Soc Nephrol,2006
3. U.S. Food and Drug Administration (2006) A Public Health Advisory. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053112.htm. [accessed 30.01.14].
4. ACR guidance document for safe MR practices: 2007;Kanal;AJR Am J Roentgenol,2007
5. European Medicines Agency. Vasovist and nephrogenic systemic fibrosis (NSF). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000418.jsp&mid=WC0b01ac058004d5c1. [accessed 30.01.14].